Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA and CD19 CAR-T cells for R/R Multiple Myeloma
NCT04194931Phase 1Unknown
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Dec 2019
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCMA CAR-T cells and CD19 CAR-T cells in multiple myeloma (MM), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
BCMA CAR-T cellsCD19 CAR-T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04194931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04194931.